Thyroid cancer is the most common malignant tumor of the endocrine system. According to GLOBOCAN 2024 estimates, approximately 960,000 new…
featured news
Vall d’Hebron Institute of Oncology (VHIO) celebrated its 20th anniversary yesterday with an institutional event at Barcelona’s Llotja de Mar,…
The ”la Caixa” Foundation has awarded funding to 80 new biomedical and health projects led by research centres, universities and…
Nicolás Anselmino, a postdoctoral researcher in the Prostate Cancer Group at the Vall d’Hebron Institute of Oncology (VHIO), has received…
On 6 and 7 October, the Vall d’Hebron Institute of Oncology (VHIO) hosted the kick-off meeting of the GLIOLIFE-AECC project….
The new school year begins, bringing the return of VHIO’s longest-running science outreach programme. Escola i Ciència welcomes schools from…
The findings pave the way for the development of new therapeutic strategies combining immunotherapy with p38α protein inhibitors. A study…
During its annual congress and coinciding with its 50th anniversary, the Spanish Society of Medical Oncology (SEOM) has awarded 70…
Developed in conjunction with The Lancet Oncology Commission on Cancer Genomics and Precision Oncology, with the contributions of over 150…
On Friday 25 September, European Researchers’ Night brought together more than 150 researchers from over 30 institutions for a day…
